Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C F Pollera

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1994
Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I studyC F Pollera, A Ceribelli, M Crecco, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1987
A randomized trial comparing alizapride alone or with dexamethasone vs a metoclopramide-dexamethasone combination for emesis induced by moderate-dose cisplatinC F Pollera, M Nardi, P Marolla, et al.
Journal of Experimental & Clinical Cancer Research : CR|June 10, 2005
A partial response in anaplastic carcinoma of the thyroid with liposomal doxorubicinL Moscetti, D Padalino, E Capomolla, et al.
Investigational New Drugs|January 1, 1997
Prolonged infusion gemcitabine: a clinical phase I study at low- (300 mg/m2) and high-dose (875 mg/m2) levelsC F Pollera, A Ceribelli, M Crecco, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1987
Cisplatin-induced hepatic toxicityC F Pollera, F Ameglio, M Nardi, et al.
Oncology|January 1, 1987
Randomized trial comparing two short courses of moderate-dose metoclopramide for moderate-dose cisplatin-induced emesisC F Pollera, E M Conti, A De Nigris, et al.
Journal of Chemotherapy (Florence, Italy)|January 26, 2006
Gemcitabine and cisplatin in the treatment of elderly patients with advanced non-small cell lung cancer: impact of comorbidities on safety and efficacy outcomeL Moscetti, F Nelli, D Padalino, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1988
Very high-dose cisplatin-induced ototoxicity: a preliminary report on early and long-term effectsC F Pollera, P Marolla, M Nardi, et al.
American Journal of Clinical Oncology|December 1, 1989
Effective control of CMF-related emesis with high-dose dexamethasone: results of a double-blind crossover trial with metoclopramide and placeboC F Pollera, M Nardi, P Marolla, et al.
Oncology|January 1, 1990
Dose and schedule effects of cisplatin on the related acute iron changesC F Pollera, F Ameglio, M Nardi, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1994
Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I studyC F Pollera, A Ceribelli, M Crecco, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1987
A randomized trial comparing alizapride alone or with dexamethasone vs a metoclopramide-dexamethasone combination for emesis induced by moderate-dose cisplatinC F Pollera, M Nardi, P Marolla, et al.
Journal of Experimental & Clinical Cancer Research : CR|June 10, 2005
A partial response in anaplastic carcinoma of the thyroid with liposomal doxorubicinL Moscetti, D Padalino, E Capomolla, et al.
Investigational New Drugs|January 1, 1997
Prolonged infusion gemcitabine: a clinical phase I study at low- (300 mg/m2) and high-dose (875 mg/m2) levelsC F Pollera, A Ceribelli, M Crecco, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1987
Cisplatin-induced hepatic toxicityC F Pollera, F Ameglio, M Nardi, et al.
Oncology|January 1, 1987
Randomized trial comparing two short courses of moderate-dose metoclopramide for moderate-dose cisplatin-induced emesisC F Pollera, E M Conti, A De Nigris, et al.
Journal of Chemotherapy (Florence, Italy)|January 26, 2006
Gemcitabine and cisplatin in the treatment of elderly patients with advanced non-small cell lung cancer: impact of comorbidities on safety and efficacy outcomeL Moscetti, F Nelli, D Padalino, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1988
Very high-dose cisplatin-induced ototoxicity: a preliminary report on early and long-term effectsC F Pollera, P Marolla, M Nardi, et al.
American Journal of Clinical Oncology|December 1, 1989
Effective control of CMF-related emesis with high-dose dexamethasone: results of a double-blind crossover trial with metoclopramide and placeboC F Pollera, M Nardi, P Marolla, et al.
Oncology|January 1, 1990
Dose and schedule effects of cisplatin on the related acute iron changesC F Pollera, F Ameglio, M Nardi, et al.
Pageof 3